Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation.
about
Public health and international drug policy.Oxycodone/Naloxone: role in chronic pain management, opioid-induced constipation, and abuse deterrenceDrug use patterns predict risk of non-fatal overdose among street-involved youth in a Canadian setting.The effect of prescription opioid injection on the risk of non-fatal overdose among people who inject drugs.Nonmedical opioid use and heroin use in a nationally representative sample of us high school seniorsSCOPE of Pain: An Evaluation of an Opioid Risk Evaluation and Mitigation Strategy Continuing Education Program.A Randomized, Double-Blind, Double-Dummy Study to Evaluate the Intranasal Human Abuse Potential and Pharmacokinetics of a Novel Extended-Release Abuse-Deterrent Formulation of OxycodoneThe effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting.Implementation Of Prescription Drug Monitoring Programs Associated With Reductions In Opioid-Related Death Rates.Perceptions of Community-Dwelling Patients and Their Physicians on OxyContin® Discontinuation and the Impact on Chronic Pain Management.Routes of abuse of prescription opioid analgesics: a review and assessment of the potential impact of abuse-deterrent formulations.Patterns of abuse and routes of administration for immediate-release hydrocodone combination products.Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program.Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain.Assessing the impact of prescribing directives on opioid prescribing practices among Veterans Health Administration providers.Gender Differences in the Association Between Religion/Spirituality and Simultaneous Polysubstance Use (SPU).Breaking barriers to novel analgesic drug development.Prescription Opioids. V. Metabolism and Excretion of Oxymorphone in Urine Following Controlled Single Dose Administration.Abuse-deterrent formulations: transitioning the pharmaceutical market to improve public health and safety.Basic/Translational Development of Forthcoming Opioid- and Nonopioid-Targeted Pain Therapeutics.Societal economic benefits associated with an extended-release opioid with abuse-deterrent technology in the United States.Relative Abuse of Crush-Resistant Prescription Opioid Tablets via Alternative Oral Modes of Administration.Pharmaceutical opioid use and harm in Australia: The need for proactive and preventative responses.Abuse-deterrent opioids: an update on current approaches and considerations.Intranasal Pharmacokinetics of Morphine ARER, a Novel Abuse-Deterrent Formulation: Results from a Randomized, Double-Blind, Four-Way Crossover Study in Nondependent, Opioid-Experienced Subjects.
P2860
Q30377895-78668E1C-5A83-4D97-9B54-3DE201ED25F3Q33938740-E004EF1E-6B3F-4ECA-8A26-5FAA2B3FD7FBQ35875932-6F85570B-DB5B-4D6E-87A3-589B941F046AQ36248958-7BF9D436-B985-4528-AB1E-2CDEE87D3250Q36421383-876DEEE3-E5FC-461F-BB7E-DD6FBA1EB2F8Q36478691-202BB80D-7027-449A-B826-3332B7533D81Q36972164-8DFA63F7-2FC0-4B72-AA57-3DF94379B6C3Q37404465-C146EC82-EE5E-4440-9100-C352142C0E6EQ37501624-C181DDE6-FC60-41B8-969E-0B5ADB425FE3Q37637803-EF39448E-5B09-4B58-9685-9A368AFEDF2BQ38632934-8D0B92CC-145B-4558-A1E7-557A784233D0Q38644058-FF303C36-E192-4748-A2CD-1791F224B5ACQ38707436-55B1432B-6D01-4522-9B6C-CB8B05F8C9A2Q38799636-0D02B9C7-121D-4C5D-ACA6-E37741124827Q38830845-7D8CE4AB-9E54-464A-9045-8D1F56FC9759Q38929162-2BD32BD2-E845-4389-8E47-D9BF9CC66D96Q39360773-08085C69-E7FE-4C25-B679-7193B152A7D0Q39609516-F2E55469-EEC9-46F5-A766-397946DA6C09Q41467838-8E953740-43AC-4BD2-AD02-453E1631D266Q43075742-358D9309-159E-45F7-A74C-73387D2E6310Q44346004-6BBD0FC4-AEDF-4F4C-8F26-5C8378DA79E6Q44349641-1DE58BF1-FBD7-4CF0-8A27-041717FB50F6Q44349704-55ECF2D2-02EA-4592-B63C-5E3FF367E311Q47274936-70582D26-DBB9-4374-99EE-497CB7FB23CBQ55073574-A8478E96-8B83-4094-B027-347C2D49D4CB
P2860
Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Changes in prevalence of presc ...... -deterrent opioid formulation.
@en
Changes in prevalence of presc ...... -deterrent opioid formulation.
@nl
type
label
Changes in prevalence of presc ...... -deterrent opioid formulation.
@en
Changes in prevalence of presc ...... -deterrent opioid formulation.
@nl
prefLabel
Changes in prevalence of presc ...... -deterrent opioid formulation.
@en
Changes in prevalence of presc ...... -deterrent opioid formulation.
@nl
P2093
P2860
P356
P1433
P1476
Changes in prevalence of presc ...... -deterrent opioid formulation.
@en
P2093
Matthew S Wieman
Pronabesh DasMahapatra
Ryan A Black
Theresa A Cassidy
P2860
P304
P356
10.1111/PME.12295
P577
2013-12-11T00:00:00Z